San Mateo, California, United States · On-site
$190k–$215k/yr
Dompé is an Italian bio-pharmaceutical company that focuses on innovation, where a long tradition in the field of personal wellness goes hand-in-hand with a commitment to research and development to meet unsatisfied ther…
Skills: Patient access, Market access, Account management, Specialty pharmacy, Payer landscape
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
The Field Access Manager minimizes access barriers for patients and healthcare providers by providing proactive account management and education on patient support programs. They act as a subject matter expert on payer policies and collaborate with internal stakeholders to optimize the patient journey.
Candidates must have at least 7 years of experience in pharma/biotech with a focus on patient or market access. A bachelor's degree is required, along with deep knowledge of CRM platforms and the specialty pharmacy landscape.
Dompé is an Italian bio-pharmaceutical company that focuses on innovation, where a long tradition in the field of personal wellness goes hand-in-hand with a commitment to research and development to meet unsatisfied therapeutic needs.
Established in 1940 in Milan, Dompé has an industrial and biotech research hub in L’Aquila, in addition to branches in Europe (Barcelona, Berlin, Paris and Tirana). The company has approximately 900 employees. The US headquarters of Dompé are based in Boston (R&D) and in the San Francisco Bay Area (Commercial Operations).
Reporting to the West Regional Director of Field Access Management, the Field Access Manager (FAM) is integral to successfully minimizing access barriers for patients and healthcare providers (HCPs) in order to optimize access to OXERVATE within their assigned geographic region. FAMs will primarily provide proactive account management support and deliver education on Dompe’s patient support programs. They will also provide acute, patient specific support to address patient access barriers.
As subject matter expert on the payer landscape for Oxervate relevant to their assigned region, FAMs will educate customers and partners on national, regional and local coverage policies and processes. They act as a conduit between the field and internal strategic functions focused on program design and patient/provider experience. FAMs anticipate, navigate and address individual account and patient access issues that occur by partnering with internal and external stakeholders including Patient Access Managers, Hub Services, Program Strategy and Design, Payer Teams, Trade, Legal, Compliance and Key Account Managers. They proactively communicate and explain Dompe- specific patient access programs, policies, procedures and resources so that HCP office staff is fluent in how to use access programs for OXERVATE. FAMs must maintain compliant relationships with all internal and external stakeholders and operate with the highest ethical and professional standards and in accordance with compliant guidelines and PRC approved materials.
Essential Functions:
Qualifications
Preferred Qualifications:
BENEFITS OF JOINING OUR TEAM
Cities/States Include:
$190,000 – 215,000 a year
At Dompe, we offer an attractive compensation package to our team members. Any offer would include a competitive base salary (estimate shared above), incentive bonus, and benefits package customary to the position. Actual individual pay is determined based on experience, qualifications, geographic location, and other job-related factors permitted by law.
We believe that the unique contributions of all employees create our success. To ensure that our products and culture continue to incorporate everyone’s perspectives and experience, we never discriminate based on race, religion, national origin, gender identity or expression, sexual orientation, age, or marital, veteran, or disability status. All your information will be kept confidential according to EEO guidelines.
We Embrace the Challenge in Science
Dompé is a private, family-owned biopharmaceutical company with more than 130 years of independent history, focused on redefining treatments for ophthalmic, neurological, and pain-related conditions through breakthrough science. As the first company to unlock the therapeutic potential of nerve growth factor (NGF), Dompé is advancing first-in-class, disease-modifying therapies that target the underlying causes of nerve damage rather than symptoms alone. Building on Nobel Prize-winning science, our work has already led to the approval of the first topical biologic in ophthalmology for a rare neurotrophic eye disease, and continues to expand into high-unmet-need areas across eye, brain, and pain indications. Our research and development model combines scientific rigor with agility. Our curiosity-driven R&D team follows the science where it leads - developing innovative biologics, advancing multiple clinical programs, and exploring new delivery platforms - to address complex and hard-to-treat diseases. Independence is central to who we are. It enables long-term thinking, sustained investment in innovation, and the ability to integrate research, manufacturing, and commercialization with the discipline of an established pharmaceutical company and the speed of a biotech. Beyond science, Dompé is deeply committed to patients, access to care, and the next generation of scientific leaders—through patient support programs and long-standing investments in education and talent development. Our mission is clear: to bring the full potential of NGF and other breakthrough molecules to patients, and in doing so, transform how diseases of the nervous system are treated.
Offices: Via Santa Lucia, Milano, Lombardia 20122, IT · Via Campo di Pile, L'Aquila, AQ 67100, IT · Via Tommaso De Amicis, 95, Naples, Campania 80145, IT · Str. ‘Sheshi Italia’, Arena Center, Entrance D, Floor 6, Unit D1/L6, Tirana, Tirana 1001, AL · 181 2nd Avenue, STE 600, San Mateo, California 94401, US
We Embrace the Challenge in Science
Dompé is a private, family-owned biopharmaceutical company with more than 130 years of independent history, focused on redefining treatments for ophthalmic, neurological, and pain-related conditions through breakthrough science. As the first company to unlock the therapeutic potential of nerve growth factor (NGF), Dompé is advancing first-in-class, disease-modifying therapies that target the underlying causes of nerve damage rather than symptoms alone. Building on Nobel Prize-winning science, our work has already led to the approval of the first topical biologic in ophthalmology for a rare neurotrophic eye disease, and continues to expand into high-unmet-need areas across eye, brain, and pain indications. Our research and development model combines scientific rigor with agility. Our curiosity-driven R&D team follows the science where it leads - developing innovative biologics, advancing multiple clinical programs, and exploring new delivery platforms - to address complex and hard-to-treat diseases. Independence is central to who we are. It enables long-term thinking, sustained investment in innovation, and the ability to integrate research, manufacturing, and commercialization with the discipline of an established pharmaceutical company and the speed of a biotech. Beyond science, Dompé is deeply committed to patients, access to care, and the next generation of scientific leaders—through patient support programs and long-standing investments in education and talent development. Our mission is clear: to bring the full potential of NGF and other breakthrough molecules to patients, and in doing so, transform how diseases of the nervous system are treated.
Offices: Via Santa Lucia, Milano, Lombardia 20122, IT · Via Campo di Pile, L'Aquila, AQ 67100, IT · Via Tommaso De Amicis, 95, Naples, Campania 80145, IT · Str. ‘Sheshi Italia’, Arena Center, Entrance D, Floor 6, Unit D1/L6, Tirana, Tirana 1001, AL · 181 2nd Avenue, STE 600, San Mateo, California 94401, US
